Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic

Oguejiofor, K., Galletta-Williams, H., Dovedi, S. J., Roberts, D. L., Stern, P. L., & West, C. M. (2017). Oncotarget, 8(9), 14416. DOI: 10.18632/oncotarget.14796. PMID: 28122336

Authors: Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CM

Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362415/

Issue: Oncotarget. 2017 Feb 28;8(9):14416-14427

PMID: 28122336

 

Abstract

Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8+ T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).